DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Benefix (Coagulation Factor IX (Recombinant)) - Published Studies


Benefix Related Published Studies

Well-designed clinical trials related to Benefix (Coagulation Factor IX)

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. [2011.02]

First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. [2010.08.10]

Coagulation factors II, V, IX, X, XI, and XII, plasminogen, and alpha-2 antiplasmin and risk of coronary heart disease. [2010.04.30]

Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. [2009.10.01]

Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. [2002.02]

Well-designed clinical trials possibly related to Benefix (Coagulation Factor IX)

Vascular effects of ultrafine particles in persons with type 2 diabetes. [2010.12]

Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study. [2010.11]

Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. [2010.06.20]

Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. [2010.03]

Phosphorylcholine-coated circuits improve preservation of platelet count and reduce expression of proinflammatory cytokines in CABG: a prospective randomized trial. [2009.07]

Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors. [2008.07]

Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. [2008.06.03]

A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. [2008.05]

Percutaneous liver biopsy in hemophiliac children with chronic hepatitis C virus infection. [2008.04]

p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. [2008.04]

Far infrared therapy inhibits vascular endothelial inflammation via the induction of heme oxygenase-1. [2008.04]

Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. [2008.03]

A heparin-bonded vascular graft generates no systemic effect on markers of hemostasis activation or detectable heparin-induced thrombocytopenia-associated antibodies in humans. [2008.02]

Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. [2008]

First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. [2007.12.04]

Prevention of haemophilic synovitis: prophylaxis. [2007.11]

Dosing factor VIIa (recombinant) in nonhemophiliac patients with bleeding after cardiac surgery. [2007.09.01]

A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. [2007.09]

Warfarin cessation before cardiopulmonary bypass: lessons learned from a randomized controlled trial of oral vitamin K. [2007.07]

Comparison of the effects of tibolone and estrogen therapy on hemostasis in surgical menopause: a randomized, double-blind, placebo-controlled study. [2007.04]

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. [2007.01.15]

First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. [2006.12.05]

Assessing Efficacy and Therapeutic Claims in Emerging Indications for Recombinant Factor VIIa: Regulatory Perspectives. [2006.01]

Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: An open, prospective randomized controlled trial. [2006]

Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: An open, prospective randomized controlled trial. [2005.09.20]

Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash. [2005.01.08]

Comparing hand-held computers and paper diaries for haemophilia home therapy: a randomized trial. [2004.11]

Prophylaxis in factor IX deficiency product and patient variation. [2003.05]

Influence of selenium-enriched yeast supplementation on biomarkers of oxidative damage and hormone status in healthy adult males: a clinical pilot study. [2002.11]

Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. [2002.04]

Effects of hormone replacement on hemostasis in spontaneous menopause. [2001.06]

Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. [2001.05.29]

Use of factor IX complex in warfarin-related intracranial hemorrhage. [1999.11]

No indication for APTT screening in patients on oral anticoagulant therapy. [1999.03]

A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate. [1998.12]

Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. [1998.11]

Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. [1997.01.15]

High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC. [1996.07]

Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. [1990.12.15]

Other research related to Benefix (Coagulation Factor IX)

The first recombinant FVIII produced in human cells--an update on its clinical development programme. [2014]

A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. [2013]

Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. [2011.07.15]

Basic hemostatic parameters in patients with long-term oral anticoagulation undergoing cholecystectomy. [2011.06]

Self-management of oral anticoagulation therapy--methodological and clinical aspects. [2011.05]

International normalized ratio versus plasma levels of coagulation factors in patients on vitamin K antagonist therapy. [2011.04]

Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. [2011.01]

Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine(R) SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis. [2011.01]

A new drug form of blood coagulation factor IX: red blood cell-entrapped factor IX. [2010.10]

Management of third molar removal with a single dose of recombinant Factor IX (BeneFIX) and local measures in severe haemophilia B. [2010.09]

[Analysis of thirteen cases with secondary coagulation disorder caused by raticide exposure]. [2010.08]

Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go? [2010.07]

Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B. [2010.05]

Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. [2010.04.13]

Discard tubes are not necessary when drawing samples for specialized coagulation testing. [2010.04]

Venous thrombosis of the upper extremity: effect of blood group and coagulation factor levels on risk. [2010.04]

Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. [2010.03]

Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal. [2010.03]

Effects of L-Carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients. [2010]

First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. [2010]

Changes in blood coagulation-related parameters in phenobarbital-treated rabbits. [2009.10]

Effects of soy consumption on oxidative stress, blood homocysteine, coagulation factors, and phosphorus in peritoneal dialysis patients. [2009.09]

Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. [2009.07.23]

Thrombin generation and coagulation factor activities: evaluation and comparison with the international normalized ratio. [2009.07]

Prospective longitudinal study of coagulation profiles in children with hypoplastic left heart syndrome from stage I through Fontan completion. [2009.04]

Effect of elevated levels of coagulation factors on the risk of venous thrombosis in long-distance travelers. [2009.02.26]

Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass. [2009.01]

L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia. [2008.08]

Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing. [2008.07]

Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients. [2008.06.15]

Vitamin K-induced modification of coagulation phenotype in VKORC1 homozygous deficiency. [2008.05]

Characterization of the coagulation deficit in porcine dilutional coagulopathy and substitution with a prothrombin complex concentrate. [2008.04]

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. [2008.04]

The neonatal coagulation system and the vitamin K deficiency bleeding - a mini review. [2008]

Change of coagulation parameters after double plateletpheresis. [2007.10]

Successful emergency reversal of phenprocoumon anticoagulation with prothrombin complex concentrate: a prospective clinical study. [2007.09]

Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. [2007.08]

Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. [2007.05]

Recombinant-activated coagulation factor VIIa (NovoSeven(R)): current development. [2007.05]

Prophylactic and therapeutic use of recombinant activated factor VII in patients with cirrhosis and coagulation impairment. [2007.05]

Continuous infusion of coagulation factors: current opinion. [2006.09]

[New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors] [2006]

Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. [2005.11]

Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. [2005.06]

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. [2005.01.15]

A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. [2004.11]

Inhibitors in congenital coagulation disorders. [2004.11]

Non-fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX. [2004.07]

Coagulation factors with improved properties for hemophilia gene therapy. [2004.04]

Specific detection of human coagulation factor IX in cynomolgus macaques. [2004.02]

Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution. [2003.11]

Thrombophilic families with inheritably associated high levels of coagulation factors VIII, IX and XI. [2003.10]

[Quality control of recombinant adeno-associated virus type 2/human blood coagulation factor IX] [2003.09]

Clinical significance of gene-diagnosis for defects in coagulation factors and inhibitors. [2003.08.14]

Random analysis of amino acid pairs sensitive to variants in human coagulation factor IX precursor. [2003.07]

The future of recombinant coagulation factors. [2003.05]

Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. [2003.03]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017